Diﬀuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin’s lymphoma (NHL). Among DLBLC patients, a small subset (5-10%) holds MYC oncogene rearrangements. Patients with this oncogene rearrangement who undergo treatment with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy are known to have a poor prognosis.
A recent study by Savage et al. published in Blood [...]
CLL patients with high-risk cytogenetics are known to have poor prognosis and limited therapeutic options. Lenalidomide – an immunomodulator with a similar chemical proﬁle to thalidomide – has demonstrated some clinical beneﬁt for these patients.
A recent study, published in the January issue of Leukemia and Lymphoma was conducted to determine the activity of the lenalidomide among patients with high-risk [...]
Two tyrosine kinase inhibitors – dasatinib and nilotinib – have shown signiﬁcant clinical activity in imatinibresistant or imatinib-intolerant chronic myeloid leukemia (CML). Choosing the most appropriate therapy in the face of imatinib failure is a matter of some debate.
Imatinib is an important breakthrough drug credited with revolutionizing the treatment of CML. However, resistance to the drug has emerged as [...]
Miraca Life Sciences, an industry leader in molecular techniques for both solid tumor and hematopoietic malignancies, is pleased to announce the launch of three important molecular assays performed by gene sequencing for blood disorders: JAK2 exon 12, cMPL, and BCR/ABL kinase domain mutation analysis.
JAK2 exon 12 and cMPL are important assays for determining the nature of certain myeloproliferative disorders [...]
The importance of quality physicians’ notes and the complete documentation of clinical history for all specimens submitted to the pathology laboratory cannot be understated.
Miraca Life Sciences is committed to providing unmatched service to our physician clients and their patients. Our best work starts in partnership with our client at the physicians’oﬃce or point of specimen collection. The documentation we [...]